Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670530 | 0.87 | DCTPP1 (0.65) | DCTPP1ALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL4672611 | 0.86 | DCTPP1 (0.64) | DCTPP1ALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL14282225 | 0.82 | NPBWR1 (0.51) | DCTPP1ALDH1A1SMN1; SMN2RXFP1IDE | |
| SCHEMBL14221005 | 0.81 | DCTPP1 (0.64) | DCTPP1ALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL13219453 | 0.80 | ALDH1A1 (0.59) | DCTPP1ALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL14282313 | 0.80 | NPBWR1 (0.52) | DCTPP1ALDH1A1SMN1; SMN2KDM4ERXFP1 | |
| SCHEMBL14282447 | 0.80 | NPBWR1 (0.50) | DCTPP1ALDH1A1SMN1; SMN2KDM4ERXFP1 | |
| SCHEMBL4675758 | 0.78 | CA12 (0.56) | DCTPP1ALDH1A1SMN1; SMN2CA12CA1 | |
| SCHEMBL4672310 | 0.78 | DCTPP1 (0.62) | DCTPP1ALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL14282453 | 0.77 | NPBWR1 (0.44) | DCTPP1ALDH1A1SMN1; SMN2RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | DCTPP1 703/4885ALDH1A1 655/4885SMN1; SMN2 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.